Subject matter, scope and second medical use — defining double patenting
By Paul Inman
In a recent Technical Board of Appeal decision, the European Patent Office (EPO) has shed some light upon the boundaries of the prohibition against double patenting.
On 12 July 1999, the Board of Regents of the University of Texas System (UTS) made an application (application number 99940802.4) for a patent related to uses of antibodies to aminophospholipids for cancer treatment. This application was granted on 22 September 2004 as European patent EP 1 096 955 B1 (EP1).
On the same date, UTS also applied for a divisional patent of EP1 under application number 04007843.8. This divisional was subsequently published as EP 1 520 588 A2 (EP2) and also related to uses of antibodies to aminophospholipids for cancer treatment…
Click on the link below to read the rest of the Wragge Lawrence Graham & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
The Treasury has issued a consultation document that clearly signals its recognition of the value to the UK economy of the private funds sector (including private equity and real estate funds).
Without prejudice communications with a regulator; collateral benefit and negligence; and more.